Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Nektar (Nasdaq: NKTR) will host an investor conference call and live webcast to review topline 36-week induction results from the ongoing Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin for severe-to-very-severe alopecia areata.

Rhea-AI Summary

Nektar (Nasdaq: NKTR) will host an investor conference call and live webcast to review topline 36-week induction results from the ongoing Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin for severe-to-very-severe alopecia areata.

The event is scheduled for December 16, 2025 at 8:00 AM ET / 5:00 AM PT. Results will be released in a morning press release and presented on the webcast; slides and the press release will be posted in the company's events section at https://ir.nektar.com/events-and-presentations/events. A replay will be available for at least 30 days after the event.

Argus Dec 16 session

-7.77% close to close Open Argus

Details

News Market Reaction – NKTR

On Dec 16, the first trading day after this news, NKTR closed 7.77% below the previous close.

Data tracked by StockTitan Argus for the Dec 16 session.

Market Context

On Dec 16, the first trading day after this news, the stock closed 7.8% below the previous close. A ...

Analysis

On Dec 16, the first trading day after this news, the stock closed 7.8% below the previous close. A negative reaction despite this procedural announcement would contrast with prior aligned responses to news, including positive moves after REZOLVE-AD data on Nov 8. In that case, traders may have focused on risk around the upcoming topline alopecia areata results or on recent financing activity and insider sales. Historically, Nektar’s shares often moved with news direction, so a sharp decline could reflect heightened sensitivity to trial outcomes.

Key Figures

Induction period length: 36 weeks Trial phase: Phase 2b Call date: December 16, 2025 +3 more

Induction period length

36 weeks

Induction treatment period in REZOLVE-AA Phase 2b trial

Trial phase

Phase 2b

REZOLVE-AA study of rezpegaldesleukin in alopecia areata

Call date

December 16, 2025

Scheduled topline results conference call and webcast

Event time ET

8:00 am ET

Start of topline results investor call

Event time PT

5:00 am PT

Start of topline results investor call

Webcast replay length

30 days

Replay availability following the topline results webcast

Historical Context

5 past events · Latest: Dec 05

5 events

1. Dec 05

   Equity inducement grants

   24h Move

   +0.7%

   Reported stock option inducement grants for two new hires under 2025 plan.

2. Nov 08

   Clinical data update

   24h Move

   +3.6%

   Phase 2b REZOLVE-AD data showed significant efficacy in asthma and dermatitis.

3. Nov 06

   Quarterly earnings

   24h Move

   +1.6%

   Q3 2025 results with cash runway to Q2 2027 and recent capital raises.

4. Oct 30

   Conference participation

   24h Move

   +5.3%

   Announced Jefferies Global Healthcare Conference fireside chat and webcast.

5. Oct 28

   Earnings date notice

   24h Move

   -2.6%

   Scheduled Q3 2025 earnings release and investor conference call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2b, regulatory t-cell (treg), alopecia areata, webcast

4 terms

phase 2b medical

"ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

regulatory t-cell (treg) medical

"rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe"

Regulatory T cells (Tregs) are a specialized type of immune cell that act like peacekeepers, calming or restraining other immune cells to prevent excessive inflammation or attacks on the body’s own tissues. For investors, Tregs matter because they are key targets or safety considerations in drug development: boosting them can treat autoimmune disease while blocking them can help cancer therapies, so therapies that affect Tregs can drive both efficacy and risk.

alopecia areata medical

"rezpegaldesleukin ... for severe-to-very-severe alopecia areata on Tuesday, December 16"

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, causing round patches of hair loss on the scalp or body; severity ranges from small spots to widespread baldness. Investors watch it because successful treatments, clinical trial results, regulatory approvals, or shifts in prevalence can create or shrink markets for drugs and therapies, affecting the value of companies developing remedies—think of it as demand risk and regulatory risk for hair-loss products.

webcast technical

"will host an investor call and live webcast to review topline results"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET / 5:00 am PT. 

Conference Call

The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK.

The event, the press release and the slides will also be available on the events section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following the event.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

For Investors:
Vivian Wu
628-895-0661

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820

For Media:

Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-induction-treatment-period-for-its-rezolve-aa-phase-2b-study-of-rezpegaldesleukin-in-alopecia-areata-on-december-16-2025-302642737.html

SOURCE Nektar Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nektar (NKTR) present topline REZOLVE-AA 36-week results?

Nektar will present topline results on December 16, 2025 at 8:00 AM ET / 5:00 AM PT.

Where can investors watch the Nektar (NKTR) REZOLVE-AA webcast on December 16, 2025?

Investors can access the live webcast via the company events page at https://ir.nektar.com/events-and-presentations/events.

Will Nektar (NKTR) release results before the webcast on December 16, 2025?

Yes. The company will provide a morning press release with the topline results before the webcast.

How long will the Nektar (NKTR) webcast replay be available after the December 16, 2025 presentation?

A replay of the webcast will be available for at least 30 days following the event.

What trial period do the presented REZOLVE-AA results cover for Nektar (NKTR)?

The presentation covers topline data from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial.

What is rezpegaldesleukin, the drug discussed by Nektar (NKTR) on December 16, 2025?

Rezpegaldesleukin is described as an investigational regulatory T-cell (Treg) proliferator being studied for severe-to-very-severe alopecia areata.